Temsirolimus in the treatment of mantle cell lymphoma: Frequency and management of adverse effects

Current Opinion in Oncology

Volumn 25, Issue SUPPL. 2, 2013, Pages

  Bouabdallah, Krimo ^a   Ribrag, Vincent ^b   Terriou, Louis ^c   Soria, Jean Charles ^b   Delarue, Richard ^d  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENHYDRAMINE; HYDROXYZINE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TEMSIROLIMUS;

ABDOMINAL PAIN; ANEMIA; ARTICLE; ASTHENIA; DATA BASE; DIARRHEA; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EXTRAVASATION; FATIGUE; FETUS MALFORMATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERSENSITIVITY; HYPERTRIGLYCERIDEMIA; INCIDENCE; LOW DRUG DOSE; MANTLE CELL LYMPHOMA; MENTAL DISEASE; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; SEXUAL DYSFUNCTION; STOMATITIS;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; SIROLIMUS;

EID: 84873650548     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835de8ee     Document Type: Article

References (45)

1. Smedby KE, HjalgrimH. Epidemiology and etiology ofmantle cell lymphomaand other non-Hodgkin lymphoma subtypes. Semin Cancer Biol 2011; 21:293-298.
2. Czuczman MS, Leonard JP, Williams ME. Clinical roundtable monograph: recent advances in the treatment of mantle cell lymphoma-a post-ASH 2009 discussion. Clin Adv Hematol Oncol 2010; 8:1-14; quiz 12p following page 14.
3. Chang JE, Kahl BS. Current status of targeted therapies for mantle cell lymphoma. Drugs 2011; 71:2307-2326.
4. Samad N, Younes A. Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. Onco Targets Ther 2010; 3:167-178.
5. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27:511-518.
6. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas; 2012. V.2., http://www.nccn.org/ professionals/physician-gls/pdf/nhl.pdf. [Accessed 4 April 2012]
7. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006; 5:671-688.
8. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005; 23:5347-5356.
9. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27:3822-3829.
10. European Medicines Agency Torisel: summary of product characteristics [online]; 2010. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/000799/WC500039912.pdf. [Accessed 5 April 2012]
11. Ansell SM, Inwards DJ, Rowland KM Jr, et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008; 113:508-514.
12. Hess G. Temsirolimus for the treatment of mantle cell lymphoma. Expert Rev Hematol 2009; 2:631-640.
13. Wyeth Pharmaceuticals. Torisel (temsirolimus) package insert; 2012: Philadelphia.
14. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12:361-368.
15. Pfizer Limited. Torisel: summary of product characteristics; 2012.
16. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271-2281.
17. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28:4996-5010.
18. De Masson A, Fouchard N, Mery-Bossard L, Dauendorffer JN. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors. Dermatology 2011; 223:4-8.
19. Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in nonmantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010; 28:4740-4746.
20. Kasiske BL, de Mattos A, Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384-1392.
21. Hoogeveen RC, Ballantyne CM, Pownall HJ, et al. Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients. Transplantation 2001; 72:1244-1250.
22. Elloso MM, Azrolan N, Sehgal SN, et al. Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice. Am J Transplant 2003; 3:562-569.
23. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006; 42:1875-1880.
24. Hadoux J, Vignot S, De La Motte Rouge T. Renal cell carcinoma: focus on safety and efficacy of temsirolimus. Clin Med Insights Oncol 2010; 4:143-154.
25. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528-538.
26. Maroto JP, Hudes G, Dutcher JP, et al. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011; 29:1750-1756.
27. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0; 2006. http://ctep.cancer.gov/protocolDevelopment/electronic-appli cations/docs/ctcaev3.pdf. [Accessed 13 September 2012]
28. Borders EB, Bivona C, Medina PJ. Mammalian target of rapamycin: biological function and target for novel anticancer agents. Am J Health Syst Pharm 2010; 67:2095-2106.
29. Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53:917-930.
30. Bellmunt J, Szczylik C, Feingold J, et al. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008; 19:1387-1392.
31. National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology. Cancer-related fatigue; 2012. V.1, http://www. nccn.org/profes sionals/physician-gls/PDF/fatigue.pdf. [Accessed 4 April 2012]
32. Ryan JL, Carroll JK, Ryan EP, et al. Mechanisms of cancer-related fatigue. Oncologist 2007; 12 (Suppl 1):22-34.
33. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40:2293-2306.
34. Meric JB, Morere JF. Anemia in lung cancer patients. Bull Cancer 2005; 92:439-444.
35. Hoy SM, McKeage K. Temsirolimus: in relapsed and/or refractory mantle cell lymphoma. Drugs 2010; 70:1819-1829.
36. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Saf 1995; 12:245-255.
37. OMé DIT Centre-Commission Anticancé reux Dossier du CNHIM (Centre National Hospitalier d'Information sur le Médicament Anticancé reux): Utilisation pratique 6ème é dition. 2008. XXIX, 5-6 http://www.oncocen tre.org/velcadom/33-conduite-extravasation.pdf. [Accessed 13 September 2013]
38. Bessede T, Massard C, Albouy B, et al. Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors. AnnOncol 2011; 22:2320-2324.
39. Huyghe E, Zairi A, Nohra J, et al. Gonadal impact of target of rapamycin inhibitors (sirolimus and everolimus) in male patients: an overview. Transpl Int 2007; 20:305-311.
40. Fritsche L, Budde K, Dragun D, et al. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004; 4:130-131.
41. Kaczmarek I, Groetzner J, Adamidis I, et al. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004; 4:1084-1088.
42. Chu SH, Liu KL, Chiang YJ, et al. Sirolimus used during pregnancy in a living related renal transplant recipient: a case report. Transplant Proc 2008; 40: 2446-2448.
43. Harrison C. Psychiatric disorders: targeting a PI3K subunit in schizophrenia. Nat Rev Drug Discov 2012; 11:602.
44. Karege F, Perroud N, Burkhardt S, et al. Alterations in phosphatidylinositol 3-kinase activity and PTEN phosphatase in the prefrontal cortex of depressed suicide victims. Neuropsychobiology 2011; 63:224-231.
45. Pfizer Limited. Torisel clinical trial report (data on file).